Cancer drug may be a possible treatment for multiple scleros
Posted: Thu Feb 21, 2013 7:54 am
Cancer drug may be a possible treatment for multiple sclerosis
A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, which was made by researchers at Karolinska Institutet, might one day lead to better forms of treatment for patients with MS.
Multiple sclerosis is a disease in which the immune system attacks the spinal cord and brain, damaging nerve tissues to cause visual impairment, paralysis and other neurological disabilities. There are approximately 17,000 MS victims in Sweden, most of who develop the disease between the age of 20 and 40. The disease is currently incurable, and the treatments that are able to ameliorate the symptoms can have severe side effects.
"There is a particularly urgent need to find new, efficacious drugs with minimal adverse effects for patients with MS in the relapsing phase of the disease," says Assistant Professor Ingrid Nilsson at Karolinska Institute's Department of Medical Chemistry and Biophysics. .... Read More - http://www.ms-uk.org/index.cfm/MSnews
A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, which was made by researchers at Karolinska Institutet, might one day lead to better forms of treatment for patients with MS.
Multiple sclerosis is a disease in which the immune system attacks the spinal cord and brain, damaging nerve tissues to cause visual impairment, paralysis and other neurological disabilities. There are approximately 17,000 MS victims in Sweden, most of who develop the disease between the age of 20 and 40. The disease is currently incurable, and the treatments that are able to ameliorate the symptoms can have severe side effects.
"There is a particularly urgent need to find new, efficacious drugs with minimal adverse effects for patients with MS in the relapsing phase of the disease," says Assistant Professor Ingrid Nilsson at Karolinska Institute's Department of Medical Chemistry and Biophysics. .... Read More - http://www.ms-uk.org/index.cfm/MSnews